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resident CSCs, 5 spontaneous cardiac repair does not occur after infarction and the necrotic tissue is not restored by intact myocardium. 6 Myocyte and vessel formation, mediated by activation and lineage specification of resident CSCs, is restricted to the surviving myocardium, while apoptosis of CSCs distributed within the ischemic region of the ventricular wall prevents tissue reconstitution allowing the evolution of the healing process and the generation of a thick, nonfunctional scar. This inevitable progression of myocardial infarction establishes the basis for cell therapy and the search for the most appropriate cell for the replacement of a non-contracting scar with mechanically efficient cardiomyocytes, and arterioles and capillaries integrated with the main coronary circulation. The lack of endogenous regeneration after infarction is not restricted to the human heart but is present in solid and non-solid organs including the skin, liver, intestine, kidney, and bone marrow. In all cases, occlusion of a supplying artery leads to scar formation mimicking cardiac pathology. 7 The stem cell compartment is properly equipped to regulate tissue homeostasis 8 but does not respond effectively to ischemic injury, or late in life to aging and senescence of the organ and organism. 8, 9 Shortly after the experimental evidence that hematopoietic stem cells (HSCs) induce myocardial regeneration after infarction, unfractionated mononuclear bone marrow cells and CD34 positive cells were administered to patients affected by acute and chronic myocardial infarction, dilated cardiomyopathy, and refractory angina. Although the individual outcomes have been inconsistent and variability exists among trials, meta-analyses of pooled data indicate that bone marrow cell therapy results in a 3-4% increase in ejection fraction, reduction in infarct size and left ventricular end-systolic volume, together with decreases in left ventricular enddiastolic volume, and improved survival. 10 The positive consequences of bone marrow cells have consistently been documented regardless of the differences in the type of cells injected, choice of o the human heart but is present in solid and non-solid organs including the skin n, , li li ive ve v r, r, i i int nt ntes es esti tine n , kidney, and bone marrow. In all cases, occlusion of a supplying artery leads to scar formation mi mimi mi mick ck cki in ing g g ca ca ardia ia ac c c p pathology. 7 The stem cell com om mp pa artment is prop op perly y e e eq qu quipped to regulate tissue h ho hom me meostasis 8 8 b but ut t d d doe es s s no no ot t t re re resp sp spon ond d d e ef eff fe ec ct tive el ly y to i i isc c chemi mi m c c i i inj njur ury y y, o or r la lat te t in n l l lif if ife e to to agi gi g ng ng g a a a d nd nd e ene ne nesc sc scen en e ce ce e o o of f f th the e o or orga ga gan n an and d o or o ga ga gani ni nis sm sm. . 8,9 ,9 9 Shortl tly y y af af a te te ter r r th th he e e ex x xpe pe peri r r me me ment nt ntal al a e e evi vi vide de denc nc nce e th th hat at a h h hem em mat at atop op opoi oi iet et etic i i s s ste te tem m m ce ce cell ll lls s (H (H (HSC SC SCs) s) s) induce clinical end-points, methods for the evaluation of cardiac function, and the interval between the onset of the cardiac disease and bone marrow cell infusion. 10 A critical question, however, persists and will have to be answered; none of these trials has employed c-kit-positive HSCs, which provided the initial experimental evidence of significant myocardial regeneration after infarction, resulting in a dramatic improvement of ventricular performance and a significantly decreased mortality in animal models of the human disease.
Recently, allogeneic and autologous bone marrow-derived MSCs have been employed in small clinical trials, and encouraging results have been published. [11] [12] [13] Although the benefits may seem modest, these initial data highlight the need for larger randomized trials designed to critically evaluate the long-term effects of MSCs on a broader patient population. However, the mechanisms involved in the positive impact of MSCs on human beings remains to be identified.
The impossibility to permanently label the cells to be delivered and the difficulty to obtain cardiac biopsies to assess parameters consistent with myocardial regeneration leaves uncertain our understanding of the cellular processes mediating partial myocardial recovery.
Measurements of coronary blood flow suggest that vasculogenesis may be operative, while the contribution of de novo myocyte formation is uncertain. Reductions in infarct scar size speak in favor of myocardial regeneration, but unequivocal data have not been obtained yet. The most popular hypotheses include development of coronary vessels and enhanced blood supply to areas of hibernating myocardium, vasculogenesis and cardiomyogenesis, and growth activation and differentiation of resident CSCs via a paracrine effect, mediated by the release of a multiplicity of cytokines by the administered MSCs. 14 The ability of MSCs to interfere with the relevant inflammatory response associated with ischemic myocardial injury adds value to the therapeutic efficacy of this class of primitive bone marrow cells.
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Measuremen nts ts s o o of f co co coro ro ona na nary ry y b b blo lo l od od od f flo lo ow w su su sugg gg gges es est t t th th that at t v v vas a cu cu culo lo oge ge gene ne nesi si s s ma ma may y y be be be o o ope pe era ra rati ti tive ve ve, , , while the Importantly, the identification of c-kit-positive CSCs (Figure 1 ) has shifted the attention to endogenous cell processes as novel targets of cell-based therapy for the failing heart. 5, 15 The appreciation that the heart is a dynamic organ constantly renewing its cell populations 8 Clearly there is the need for more work in order to properly advance the field of cell therapy which is currently in its infancy.
The remarkable recovery in the anatomical and functional integrity of the infarcted myocardium following combined cell therapy 4 raises important questions concerning the mechanisms involved. The heart typically shows randomly oriented ellipsoid compartments where CSCs are clustered together forming myocardial niches. These pockets of CSCs are connected structurally and functionally to myocytes and fibroblasts that constitute the supporting cells within the niches; gap and adherens junctions made, respectively, by connexins and cadherins ensure the "cooperative" interaction regulating stem cell function and niche homeostasis. 3, 19 Whether the administration of MSCs and CSCs leads to the formation of modified to reach the maximum effect in animals and, ultimately, in humans. Th he e e st st tri iki ki king ng ng difference in the number of injected MSCs and CSCs makes a direct comparison between these w wo o o ce ce ell ll ll c cla la lass ss ses e e ess ss sse entially impossible, but this ha ha has to be seen as th th he be be egi gi ginn n ing of a more co om mp mplex and de dema ma mand nd din in i g g g ap ap app pr pro oa oach ch h f f for or th h he m m man n nagem em emen nt t t o of of h h hu um man an n i isc che he hem m mic c ca ca card rdio io omy my myop op pat at th hy hy. .
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temporary and/or permanent niches within the host swine myocardium has not yet been resolved and constitutes a major challenge for future research. The actual transfer of molecules between
MSCs and CSCs remains to be shown to uncover the fundamental cellular processes involved in the extensive repair of the damaged heart.
Cardiac niches create the necessary, permissive milieu for the long-term residence and growth of CSCs. 20 Similarly, the survival of exogenously administered stem cells requires their engraftment within the recipient myocardium. However, the region bordering the infarct is exposed to increased wall stress and functional demand, which promotes myocyte hypertrophy, at tte te enu nu nuat at ate e th th thi is is pro ro ob bl ble em; the delivered MSCs may y y p p pr ro ovide an enviro ro onm men en ent t t favoring the en ngr graf a tment of of C C CS SC Cs s an an nd d d th th the e e a ac acqu qu ui is si siti tion on n of f th h he ca a ard d dioge ge geni nic c c f fa fate te. .
Th The e e bo bo b rd rd der r r z zon on ne e is is ch ha hara ra act ct cter er eriz ize ed ed b b by y y an n n i i int nt ten n nse e e re e ege ge gene ne era ra rati ti ive ve e r r res es spo po ons nse e e th th hat at p p pr ro rom m mot te tes, s, i in n part, the reco ove ve very ry ry o o of f f th th he e e lo ost st s m m mus us uscl cl c e e e ma ma ass ss ss f f fol ol o lo lo lowi wi wing ng ng m myo yo yoca ca card rd rdia ia ial l l t t i i inf f far ar arct ct ctio io ion. n. n. T Thi hi his s s ad ad adap ap apta t tion favored but the long-term proliferation and self-renewal ability of exogenous and endogenous CSCs may be hampered, possibly attenuating the stability and durability of cell-based therapy in its various forms. These issues are consistent with the questions posed by Dr. Hare and his team, and collaborative efforts between laboratories with extensive experience in MSCs and CSCs are warranted in the search for the most powerful form of cell therapy for the injured human heart.
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